Neurofilament light chain is a marker of axonal damage and is of interest as a biofluid biomarker for PD. The objective of this study was to investigate whether CSF or serum neurofilament contributes to a combination of CSF biomarkers in defining the optimal biomarker panel for discriminating PD patients from healthy controls. In addition, we aimed to assess whether CSF and/or serum neurofilament levels are associated with clinical measures of disease severity.

中文翻译：

---

添加到 α-突触核蛋白面板的 CSF 或血清神经丝光可将帕金森病与对照组区分开来

神经丝轻链是轴突损伤的标志物，作为 PD 的生物流体生物标志物很受关注。本研究的目的是调查脑脊液或血清神经丝是否有助于脑脊液生物标志物的组合，以确定用于区分 PD 患者与健康对照的最佳生物标志物面板。此外，我们旨在评估脑脊液和/或血清神经丝水平是否与疾病严重程度的临床指标相关。